Tag: rare disease gene therapy post approval study data
2024 Updated FDA Gene Therapy Requirements for Rare Diseases: Safety Monitoring Rules, Insertional Mutagenesis Risks, Long-Term Efficacy, Side Effects & Post-Approval Study Data
Per 2024 FDA guidance, Johns Hopkins Bloomberg School of Public Health, and National Human Genome Research Institute data, this 2024 updated buying guide covers all rare disease gene therapy safety monitoring requirements, insertional mutagenesis risks, long-term efficacy tracking protocols, and post-approval study mandates. Premium vs counterfeit regulatory compliance tools reduce non-compliance risk by 72% for